Protocol: CALGB 30607

Contact: CPLORD@stvincent.org

Title: Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

Summary: This study is for patients with advanced stage non-small cell lung cancer that has been treated by chemotherapy. The purpose of this study is to determine if giving patient the drug called sunitinib after they respond to chemotherapy (the patient’s tumor shrinks or stops growing) will help a tumor continue to shrink or stay the same. Sunitinib is experimental (investigational) in the treatment of non-small cell lung cancer. In this study, the patient receives either sunitinib or a placebo (a substance that looks like sunitinib, but contains no medication).

–

Protocol: CALGB 30610

Contact: MRFUQUA@stvincent.org

Title: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

Summary: This study is for patients with small cell lung cancer that has not been detected outside the chest. The purpose of this study is to compare the effectiveness of three different methods to give radiation therapy. Two of the methods are experimental, while one is standard. The two experimental methods of giving the radiation therapy are: 1) once a day with a high dose of radiation for 7 weeks; or 2) once a day for 16 days of treatment (about 3 weeks), followed by twice a day for the remaining 9 days of treatment (about 2 weeks), for a total of 5 weeks. The standard method of giving the radiation therapy is to give it twice a day for 3 weeks. Everyone will receive chemotherapy with cisplatin and etoposide, which have been established through clinical trials to be standard drugs for this type of cancer. The exact doses of the chemotherapy have not been completely standardized and the patient will receive a commonly used dosing schedule.

–

Protocol: ECOG 1505

Contact: MRFUQUA@stvincent.org

Title: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (= 4cm) – IIIA Non-Small Cell Lung Cancer (NSCLC)

Summary: This study is for patients with non-small cell lung cancer, which has been surgically removed. The purpose of this study is to determine if adding the drug bevacizumab to chemotherapy improves the chance of remission. The study compares the effects of adding bevacizumab to chemotherapy with standard chemotherapy alone to determine which is more effective at preventing the cancer from recurring.

–

Protocol: LUN06-113

Contact: MRFUQUA@stvincent.org

Title: A Randomized Double Blind Phase II Trial of Platinum Therapy Plus Etoposide with/without Concurrent ZD6474 in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer

Summary: This study is to investigate new therapies for small cell lung cancer. The purpose of this study is to determine the safety and effectiveness of receiving a new drug (ZD6474) while receiving the standard treatment of cisplatin or carboplatin and etoposide versus the standard treatment of cisplatin or carboplatin and etoposide without ZD6474.

–

Protocol: RTOG 0617

Contact: CPLORD@stvincent.org

Title: A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus HIGH-DOSE (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND# 103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer

Summary: This study is for patients with lung cancer that has spread to regional lymph nodes and who are not candidates for surgery. The purpose of this study is to compare the effects of high-dose radiation therapy and chemotherapy with standard dose radiation therapy and chemotherapy on patients with this type of cancer. In this study the patient receives either the high-dose or the standard-dose radiation therapy. The high-dose radiation therapy is considered experimental. Everyone will receive the same chemotherapy schedule and combination of paclitaxel and carboplatin.

–

Protocol: Moffitt

Contact: CPLORD@stvincent.org

Title: Total Cancer Care™: A Partnership with High Risk and/or Diagnosed Cancer Patients for Life – 14690

Summary: This study is for patients undergoing surgery at the St.Vincent Indianapolis Hospital. The patient grants permission for St.Vincent Indianapolis Hospital to have access to the tissue removed, and they donate it to the Moffitt Cancer Center for use in research. This research will pursue improving cancer treatments and patients outcomes of cancer treatments, both current and future.

–

Protocol: RTOG 0937

Contact: MRFUQUA@stvincent.org

Title: Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)

Summary: This study is for patients with small cell lung cancer who did not completely respond to chemotherapy. The study compares the effects of radiation given to the brain after chemotherapy with radiation to the brain, chest, and up to three other sites that did not completely respond to treatment after chemotherapy. Group 1 patients will receive radiation to the brain daily, Monday through Friday, for two weeks. Group 2 patients will receive radiation to the brain daily, Monday through Friday, for two weeks, and radiation to the chest and other cancer sites of cancer that did not completely respond to the chemotherapy also for 2 weeks to the other sites of cancer that did not completely respond to the chemotherapy. If patients receive radiation to the chest and other sites after brain radiation is finished, they will have treatment daily, Monday-Friday, for an additional 2-3 weeks.